Vision & Mission

Combining cancer vaccines
and T-cell therapies

ErVaccine Technologies develops breakthrough immunotherapies combining cancer vaccines and T-cell therapies based on the identification of new families of tumor antigens.

We are dedicated to discover more accurate tumor epitopes that are shared between patients. We focus on non-conventional epitopes derived from endogenous retroviruses (HERVs).

Our approach is based on new bioinformatics algorithms to identify potential epitopes that are validated by proteomics and immunology assays: from bioinformatics to proteomics.

About us

Latest News

  • Published On: June 29th, 2022

    ErVaccine Technologies, a preclinical-stage biotechnology company, announces the publication of a new paper in American Journal of Hematology‘HERVs characterize normal and leukemia stem cells […]

  • Published On: June 16th, 2022

    ErVaccine Technologies, a preclinical-stage biotechnology company, today announces the publication of a new paper in European Journal of Cancer journal: ‘Tumor burden and antigen-specific T cell magnitude represent major parameters […]

  • Published On: June 9th, 2022

    ErVaccine Technologies announces an endorsement from BPI (French Deeptech support) for a non-dilutive funding in the form of grants and repayable advances, for a total amount above 1.9 million€ on […]

Latest Publications & Abstracts

  • Categories: Publications & abstractsPublished On: June 28th, 2022
  • Categories: Publications & abstractsPublished On: June 16th, 2022
  • Categories: Publications & abstractsPublished On: January 27th, 2022
  • Categories: Publications & abstractsPublished On: December 17th, 2021